Bourse FRANCE
SRD
EUROLIST A
EUROLIST B
EUROLIST C
Marche Libre
CAC 40
SBF 120
SBF 250
MIDCAC
Bourse EUROPE
Bourse Allemagne
Bourse Angleterre
Bourse Autriche
Bourse Belgique
Bourse Danemark
Bourse Espagne
Bourse Finlande
Bourse Grece
Bourse Islande
Bourse Luxembourg
Bourse Italie
Bourse Norvege
Bourse Pologne
Bourse Portugal
Bourse Pays-Bas
Bourse Suede
Bourse Suisse

Bourse Europe Est

 OUTILS
 SOCIETES
 INVESTIR
DERIVES
COMPRENDRE
LES +
COMMUNAUTE
Logiciels - Softwares Analyse Banques SICAVS & FCP Lexique Jeux Boursiers Forums
Telechargements Information Courtiers Warrants Heures de Trading Livres -Books Pages Personnels
Rapports Annuels Introductions-IPO Fiscalite Trackers Indices Emploi - Jobs Clubs d'Investissements
RADIOS
JOURNAUX
TELES WEB
Ernstrade-Lyrics
Webmasters-Affiliations
Logos-Sonneries
Ajouter aux favoris / Add favorite Ernstrade.com
Accueil
GoogleRecherche/Search
 
NYSE
AMEX
PHILADELPHIA
BOSTON
0-9
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Abiomed Inc
Nasdaq

Abiomed, Inc. is a developer, manufacturer and marketer of medical products designed to safely and effectively assist or replace the pumping function of a failing heart. The Company's FDA (Food and Drug Administration)-approved BVS is an advanced heart assist device used for temporary treatment of heart failure patients.

http://www.abiomed.com

595 U.S. Commercial Impella Patients During the Quarter 
49 Patients Enrolled in PROTECT II Study 
DANVERS, Mass., Aug 04, 2010 (BUSINESS WIRE) --



Abiomed Reports Record U.S. Impella Utilization for First Quarter of Fiscal 2011 
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2011 revenue of $22.0 million, up 11% compared to the same period of fiscal 2010. 
 

Total commercial U.S. Impella revenue, including initial site stocking orders and reorders, totaled $15.5 million, a 48% increase compared to $10.5 million in the first quarter of fiscal 2010. Commercial U.S. Impella reorders of $13.7 million were up 114% from $6.4 million in the first quarter of fiscal 2010 and represented 88% of commercial U.S. Impella revenue. 

Worldwide Impella revenue totaled $16.6 million, up 38% compared to revenue of $12.0 million in the prior year. 

Financial and operating highlights during the first quarter of fiscal 2011 include: 
 

Approximately 595 U.S. commercial patients were treated with Impella(R) 2.5, 5.0 or LD, a 74% increase compared to approximately 341 commercial patients in the first quarter of fiscal 2010. 
49 patients were enrolled in the Protect II study, for a total of 390 patients completed, or 60% of the 654 patients required. 
An additional 24 U.S. hospitals purchased Impella 2.5 for commercial use during the quarter, bringing the total to 437 commercial customers, as compared to 47 hospitals added in the first quarter of fiscal 2010. 
Gross margin rate for the first quarter of fiscal 2011 was 76%, compared to 75% in the first quarter of fiscal 2010. 
Non-Impella revenue was $5.4 million for the first quarter of fiscal 2011, 32% lower than $7.9 million in the first quarter of fiscal 2010. The decline in non-Impella revenue was attributed partially to the Company's restructuring of its surgery business and the exiting of distributors in Europe. 
GAAP net loss for the first quarter of fiscal 2011 was $6.0 million, or $0.16 per share, compared to a GAAP net loss of $7.8 million, or $0.21 per share for the first quarter of fiscal 2010. 
Non-GAAP net loss, which is described later in this press release for the first quarter of fiscal 2011 was $3.7 million, or $0.10 per share versus non-GAAP net loss of $5.7 million or $0.16 per share, in the first quarter of fiscal 2010. 
Cash, cash equivalents and short-term marketable securities totaled $54.9 million at June 30, 2010 compared to $58.3 million at March 31, 2010. 
At EuroPCR in May 2010, Abiomed announced latest results from USpella, a U.S. multicenter, observational registry of Impella 2.5(R) patients. The full presentation can be viewed here. 
 

 


 
 
 
 
 
 
 
 

Copyright  2009  Ernstrade

Bourse ETATS UNIS
Bourse NASDAQ
Bourse NYSE
Bourse ASE
Bourse Philadelphia
Bourse Boston
Bourse AMERIQUES
Bourse Bresil
Bourse Canada
Bourse Jamaique
Bourse Trinidade

Avertissement légal - Contact Webmaster - Partenaires
Positionnement et Statistiques Gratuites